NEW YORK, July 7, 2026, 12:06 (EDT)
- SkinHealth Systems shares were up around 50% near midday, trading on volume more than 50 times their 65-day average.
- The stock jumped after the company said July 7 its SkinStylus device got FDA clearance. FDA records put the 510(k) decision at Feb. 19.
- The stock traded over $1 at times during the day, which is linked to Nasdaq’s minimum bid price, but only closing bids matter for the cure.
SkinHealth Systems Inc. NASDAQ:SKIN surged in busy trading Tuesday after the medical aesthetics company announced its SkinStylus microneedling device got a fresh FDA clearance for periorbital wrinkles. Investors focused less on the approval, more on the pricing.
Shares jumped 49.9% to $1.1319 as of 12:06 p.m. EDT, moving in a range from $0.7715 to $1.17. Volume hit 60.2 million shares, well above the 65-day average of 1.17 million. That’s about 51.5 times typical volume, according to WSJ market data.
| Trading readout | Tuesday at 12:06 p.m. EDT | Comparator |
|---|---|---|
| Share price | $1.1319 | Closed last at $0.7549 |
| One-day move | Up 49.9% | DJIA off 0.34%; Russell 2000 down 0.76% |
| Volume | 60.2 million shares | 65-day average 1.17 million |
| Day range | Traded between $0.7715 and $1.17 | 52-week range is $0.5506 to $2.69 |
The jump is notable after SkinHealth said in a May filing that Nasdaq warned the stock had closed under $1 for 30 straight sessions through May 7. The company has until Nov. 4 to fix it. That would mean a closing price of $1 or more for at least 10 days in a row. Nasdaq could ask for 20 days.
A move above $1 during the day isn’t enough. The real test comes if shares finish above that level and stay there. So Tuesday’s close matters more than the intraday high.
SkinHealth said before the bell that its SkinStylus device has won clearance to treat periorbital wrinkles in all Fitzpatrick skin types. Whitney Cypes, chief brand and clinical innovation officer at SkinHealth, called the move an “important milestone.” Dr. Glynis Ablon, who led the clinical study, said SkinStylus led to “clinically meaningful improvements” in those wrinkles. GlobeNewswire
The FDA’s 510(k) database shows SkinStylus SteriLock MicroSystem (MP1209SL) got a “Substantially Equivalent” decision on Feb. 19, with the web page updated July 6. FDA Access Data
The FDA filing tightens up a detail investors should watch. The company’s July 7 release said adults 22 and up. But the FDA indication form lists periorbital-wrinkle use for people 34 and older, all Fitzpatrick skin types I-VI.
| Source | Age wording for periorbital wrinkle indication | Other detail |
|---|---|---|
| SkinHealth July 7 release | Adults 22 and older | Notes SkinStylus is cleared for facial acne scars, periorbital wrinkles, abdominal scars |
| FDA indication form | Adults 34 and older | States prescription only; for Fitzpatrick skin types I through VI |
| FDA 510(k) database | Main page doesn’t note age | Decision dated Feb. 19; last update July 6 |
The move comes as sales remain soft. In May, SkinHealth posted first-quarter net sales of $64.9 million, a drop of 6.7% from the previous year. Delivery systems sold slipped to 746 compared to 862, but the active install base increased to 36,419 from 35,014.
| Q1 metric | 2026 | 2025 | Change |
|---|---|---|---|
| Net sales | $64.9 mln | $69.6 mln | -6.7% |
| Delivery systems sold | 746 | 862 | -13.5% |
| Active install base | 36,419 | 35,014 | +4.0% |
| Adjusted EBITDA | $8.5 mln | $7.3 mln | +16.4% |
| Net loss | $6.6 mln | $10.1 mln | loss shrank |
The split helps explain the quick market reaction. A wider SkinStylus claim could push the device case and cross-sell with Hydrafacial providers, but the company still needs to convert its active customer base into more consumables and device sales. Consumables revenue dropped to $46.4 million from $49.4 million in the first quarter. Delivery systems sales were down to $18.5 million, compared to $20.2 million.
SkinHealth has some flexibility from its $204.4 million in cash, cash equivalents and restricted cash as of March 31, but that doesn’t fix its listing problem. The figure fell from $232.7 million at the end of last year. Convertible senior notes stand at $102.9 million current and $241.3 million long-term.
Trading on Tuesday circled two dates—July 7, the date the company announced the clearance, and Nov. 4, when the Nasdaq cure period is up. Now, with the FDA decision date set for Feb. 19, it’s less of a straightforward “fresh FDA win” setup on the tape.
